LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS
- Wednesday, December 22, 2021, 8:12
- Environment
- Add a comment
SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ — Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first patient has been dosed in its Phase 2 proof-of-concept clinical study (NCT04874350) for the…
About the Author
adminasapcorp has written 41672 stories on this site.